<?xml version="1.0" encoding="UTF-8"?>
<p>Drugs that can increase ACE2 activity include 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590" xmlns:xlink="http://www.w3.org/1999/xlink">losartan</ext-link> (NCT04312009, NCT04311177, NCT04340557, and NCT04343001; 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">clinicaltrials.gov</ext-link>), 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10307" xmlns:xlink="http://www.w3.org/1999/xlink">diminazene diaceturate</ext-link>, resorcinol naphthalein, and xantenone (Li et al., 
 <xref rid="bph15207-bib-0054" ref-type="ref">2020</xref>). Also, AT
 <sub>1</sub> receptor antagonists have been considered as anti‐COVID‐19 therapeutics (Gurwitz, 
 <xref rid="bph15207-bib-0032" ref-type="ref">2020</xref>). Furthermore, recombinant ACE2 has been proposed in both pneumonia (Khan et al., 
 <xref rid="bph15207-bib-0045" ref-type="ref">2017</xref>) and COVID‐19 (Monteil et al., 
 <xref rid="bph15207-bib-0062" ref-type="ref">2020</xref>).
</p>
